Opioid use affects antioxidant activity and purine metabolism: Preliminary results

Human Psychopharmacology

Volumn 24, Issue 8, 2009, Pages 666-675

  Mannelli, Paolo ^a   Patkar, Ashwin ^a   Rozen, Steve ^b   Matson, Wayne ^c   Krishnan, Ranga ^a,b   Kaddurah Daouk, Rima ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Addiction; Metabolic profiling; Metabolomics; Metabonomics; Methadone; Opioid detoxification

Indexed keywords

ALPHA TOCOPHEROL; GAMMA TOCOPHEROL; GLUTATHIONE; GLUTATHIONE DISULFIDE; GUANINE; METHADONE; OPIATE; URIC ACID; XANTHINE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; FEMALE; HUMAN; MALE; METABOLOMICS; NEUROTRANSMISSION; OPIATE ADDICTION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PURINE METABOLISM; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; ANTIOXIDANTS; FEMALE; HUMANS; MALE; METABOLOMICS; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PURINES; YOUNG ADULT;

EID: 73449104563     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1068     Document Type: Article

References (71)

1. American Psychiatric Association. 2000. Diagnostic Criteria from DSM-IVTR. American Psychiatric Association: Washington, DC.
2. Bandopadhyay D, Das D, Banerjee RK. 1999. Reactive oxygen species: oxidative damage and pathogenesis. Curr Sci 77: 658-666.
3. Barsotti C, Pesi R, Giannecchini M, Ipata P. 2005. Evidence for the involvement of cytosolic 5′-nucleotidase (cN-II) in the synthesis of guanine nucleotides from xanthosine. J Biol Chem 280: 13465-13469.
4. Beal MF, Matson WR, Swartz KJ, Gamache P, Bird E. 1990. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55: 1327-1339.
5. Bogdanov M, Matson WR, Wang L, et al. 2008. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396.
6. Boucsein C ZR, Färber K, Pavlovic S, Hanisch UK, Kettenmann H. 2003. Purinergic receptors on microglial cells: functional expression in acute brainslices and modulation of microglial activation in vitro. Eur J Neurosci 17: 2267-2276.
7. Burnstock G. 2008. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 7: 575-590.
8. Capasso A, Loizzo A. 2001. Purinoreceptors are involved in the control of acute morphine withdrawal. Life Sci 69: 2179-2188.
9. Chen LH. 1989. Interaction of vitamin E and ascorbic acid (review). In Vivo 3: 199-209.
10. Chen X, Lu G, Gong Y, et al. 2007. Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment. Cell Res 17: 689-700.
11. Christie MJ. 2008. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154: 384-396.
12. Ciccarelli R, Di Iorio P, Giuliani P, et al. 1999. Rat cultured astrocytes release guanine-based purines in basal conditions and after hypoxia/ hypoglycemia. Glia 25: 93-98.
13. Coban TA, Beydemir S, Gulcin I, Ekinci D. 2007. Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. Biol Pharm Bull 30: 2257-2261.
14. Díaz-Flores Estévez J, Díaz-Flores Estévez F, Hernández Calzadilla C, Rodríguez Rodríguez E, Díaz Romero C, Serra-Majem L. 2004. Application of linear discriminant analysis to the biochemical and haematological differentiation of opiate addicts from healthy subjects: a case-control study. Eur J Clin Nutr 58: 449-455.
15. Di Francesco P, Tavazzi B, Gaziano R, et al. 1998. Differential effects of acute morphine administrations on polymorphonuclear cell metabolism in various mouse strains. Life Sci 63: 2167-2174.
16. Enrico P, Esposito G, Mura MA, et al. 1997. Effect of morphine on striatal dopamine metabolism and ascorbic and uric acid release in freely moving rats. Brain Res 745: 173-182.
17. Espejo EF, Serrano MI, Caille S, Stinus L. 2001. Behavioral expression of opiate withdrawal is altered after prefrontocortical dopamine depletion in rats: monoaminergic correlates. Neuropsychopharmacology 25: 204-212.
18. Godefroy F, Matson WR, Gamache PH, Weil-Fugazza J. 1990. Simultaneous measurements of tryptophan and its metabolites, kynurenine and serotonin, in the superficial layers of the spinal dorsal horn. A study in normal and arthritic rats. Brain Res 526: 169-172.
19. Goudas LC, Langlade A, Serrie A, et al. 1999. Acute decreases in cerebrospinal fluid glutathione levels after intracerebroventricular morphine for cancer pain. Anesth Analg 89: 1209-1215.
20. Gulcin I, Beydemir S, Alici HA, Elmastas M, Buyukokuroglu ME. 2004. In vitro antioxidant properties of morphine. Pharmacol Res 49: 59-66.
21. Guzman J, Yu JG, Suntres Z, et al. 2006. ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflamm Bowel Dis 12: 766-789.
22. Jiang Y, Yang W, Zhou Y, Ma L. 2003. Up-regulation of murine double minute clone 2 (MDM2) gene expression in rat brain after morphine, heroin, and cocaine administrations. Neurosci Lett 352: 216-220.
23. Kaddurah-Daouk R, Kristal BS,Weinshilboum RM. 2008. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683.
24. Kaddurah-Daouk R, Mcevoy J, Baillie RA, et al. 2007. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 12: 934-945.
25. Kish SJ, Kalasinsky KS, Derkach P, et al. 2001. Striatal dopaminergic and serotonergic markers in human heroin users. Neuropsychopharmacology 24: 561-567.
26. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. 2007a. High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358: 159-174.
27. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR. 2007b. Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 371: 393-409.
28. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR. 1999. Purine catabolism: links to mitochondrial respiration and antioxidant defenses? Arch Biochem Biophys 370: 22-33.
29. Kulikowska E, Kierdaszuk B, Shugar D. 2004. Xanthine, xanthosine and its nucleotides: solution structures of neutral and ionic forms, and relevance to substrate properties in various enzyme systems and metabolic pathways. Acta Biochim Pol 51: 493-531.
30. Lenz BK. 2004. Tobacco, depression, and lifestyle choices in the pivotal early college years. J Am Coll Health 52: 213-219.
31. Linseman DA, Loucks FA. 2008. Diverse roles of Rho family GTPases in neuronal development, survival, and death. Front Biosci 13: 657-676.
32. Liu JK, Hong M, Zhao XD. 2003. Effect of morphine on expression of gene of enzymes related to purine nucleotide metabolism in c6 glioma. Zhonghua Yi Xue Za Zhi 83: 46-50.
33. Liu C, Liu JK, Kan MJ, et al. 2007. Morphine enhances purine nucleotide catabolism in vivo and in vitro. Acta Pharmacol Sin 28: 1105-1115.
34. Loeffler DA, Camp DM, Juneau PL, Harel E, Lewitt PA. 2000. Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells. Brain Res Bull 52: 553-558.
35. Loeffler DA, Lewitt PA, Juneau PL, et al. 1998. Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover. Brain Res Bull 45: 297-299.
36. Macedo T, Ribeiro CA, Cotrim D, et al. 1995. Catecholamine and MHPG plasma levels, platelet MAO activity, and 3H-imipramine binding in heroin and cocaine addicts. Mol Neurobiol 11: 21-29.
37. Majumder P, Trujillo CA, Lopes CG, et al. 2007. New insights into purinergic receptor signaling in neuronal differentiation, neuroprotection, and brain disorders. Purinergic Signal 3: 317-331.
38. Manji H, Chen G, Potter W, Kosten TR. 1997. Guanine nucleotide binding proteins in opioid-dependent patients. Biol Psychiatry 41: 130-134.
39. Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E. 2009. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol 14(2): 204-213.
40. McLellan AT, Kushner H, Metzger D, et al. 1992. The fifth edition of the addiction severity index. J Subst Abuse Treat 9: 199-213.
41. Miskevich DA, Petushok NE, Lelevich VV, Lelevich SV, Borodinskii AN. 2007. Effect of chronic morphine treatment on free radical state. Biomed Khim 53: 190-195.
42. Mori N, Yasutake A, Hirayama K. 2007. Comparative study of activities in reactive oxygen species production/defense system in mitochondria of rat brain and liver, and their susceptibility to methylmercury toxicity. Arch Toxicol 81: 769-776.
43. Niwa T, Takeda N, Yoshizumi H. 1998. RNA metabolismin uremic patients: accumulation of modified ribonucleosides in uremic serum. Technical note. Kidney Int 53: 1801-1806.
44. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. 2007. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 22: 418-423.
45. Pan J, Zhang Q, Zhang Y, Ouyang Z, Zheng Q, Zheng R. 2005. Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 77: 183-193.
46. Pancehnko LF, Peregud DI, Iakovlev AA, et al. 2004. Effects of morphine withdrawal on the indices of free radical homeostasis and nitric oxide system in rat liver and thymus. Biomed Khim 50: 460-470.
47. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J. 2007. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 114: 959-968.
48. Payabvash S, Beheshtian A, Salmasi A, et al. 2007. Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci 79: 972-980.
49. Pereska Z, Dejanova B, Bozinovska C, Petkovska L. 2007. Prooxidative/ antioxidative homeostasis in heroin addiction and detoxification. Bratisl Lek Listy 108: 393-398.
50. Qiusheng Z, Yuntao Z, Rongliang Z, Dean G, Changling L. 2005. Effects of verbascoside and luteolin on oxidative damage in brain of heroin treated mice. Pharmazie 60: 539-543.
51. Rathbone MP, Middlemiss PJ, Gysbers JW, et al. 1999. Trophic effects of purines in neurons and glial cells. Prog Neurobiol 59: 663-690.
52. Rodriguez-Delgado MA, Diaz-Flores Estevez JF, Diaz-Flores Estevez F, Hernandez Calzadilla C, Diaz Romero C. 2002. Fast determination of retinol and alpha-tocopherol in plasma by LC. J Pharm Biomed Anal 28: 991-997.
53. Rozen S, Cudkowicz ME, Bogdanov M, et al. 2005. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1: 101-108.
54. Schmidt AP, Lara DR, Souza DO. 2007. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Ther 116: 401-416.
55. Sharma H, Sjöquist P, Ali S. 2007. Drugs of abuse-induced hyperthermia, blood-brain barrier dysfunction and neurotoxicity: neuroprotective effects of a new antioxidant compound H-290/51. Curr Pharm Des 13: 1903-1923.
56. Sies H. 1991. Oxidative stress: from basic research to clinical application. Am J Med 91: 31S-38S.
57. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440-9445.
58. Takeda N. 1994. Serotonin-degradative pathways in the toad (Bufo bufo japonicus) brain: clues to the pharmacological analysis of human psychiatric disorders. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 107: 275-281.
59. Takeda N, Ikeda R, Ohba K, Kondo M. 1995. Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport 6: 2378-2380.
60. Turgan N, Boydak B, Habif S, et al. 1999. Urinary hypoxanthine and xanthine levels in acute coronary syndromes. Int J Clin Lab Res 29: 162-165.
61. Ueda H, Inoue M, Mizuno K. 2003. New approaches to study the development of morphine tolerance and dependence. Life Sci 74: 313-320.
62. Uemura Y, Kowall NW, Beal MF. 1991. Global ischemia induces NMDA receptor-mediated c-fos expression in neurons resistant to injury in gerbil hippocampus. Brain Res 542: 343-347.
63. Volicer L, Langlais PJ, Matson WR, Mark K, Gamache PH. 1985. Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. Arch Neurol 42: 1158-1161.
64. Walsh M, Brennan L, Pujos-Guillot E, et al. 2007. Influence of acute phytochemical intake on human urinary metabolomic profiles. Am J Clin Nutr 86: 1687-1693.
65. Wesson DR, LingW. 2003. The Clinical OpiateWithdrawal Scale (COWS). J Psychoactive Drugs 35: 253-259.
66. Xu B, Wang Z, Li G, et al. 2006. Heroin-administered mice involved in oxidative stress and exogenous antioxidant-alleviated withdrawal syndrome. Basic Clin Pharmacol Toxicol 99: 153-161.
67. Yamamoto T, Moriwaki Y, Takahashi S. 2005. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid). Clin Chim Acta 356: 35-57.
68. Zakhari S, Li T. 2007. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology 46: 2032-2039.
69. Zhang YT, Zheng QS, Pan J, Zheng RL. 2004. Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. Basic Clin Pharmacol Toxicol 95: 53-58.
70. Zhou J, Si P, Ruan Z, et al. 2001. Primary studies on heroin abuse and injury induced by oxidation and lipoperoxidation. Chin Med J (Engl) 114: 297-302.
71. Zhou JF, Yan XF, Ruan ZR, et al. 2000. Heroin abuse and nitric oxide, oxidation, peroxidation, lipoperoxidation. Biomed Environ Sci 13: 131-139.